GenSight Biologics reports its cash position as of September 30, 2016

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

GenSight Biologics announces successful IPO on Euronext Paris

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

Sight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future

GenSight Biologics announced today the closing of a €32 million Series A financing for Ophthalmic Gene Therapy.